Squawk on the Street Cramer's Morning Take: Bristol Myers 4/24/25
Apr 24, 2025
A deep dive into Bristol Myers' latest quarterly performance reveals successful revenue and earnings, highlighting the significance of new drug developments. The discussion also clears up trial myths about schizophrenia treatment. Confidence levels in various corporations are analyzed, showcasing contrasts with companies like GE Healthcare and Constellation Brands. Listeners are urged to stay cautious about investment risks while remaining optimistic about potential positive developments.
AI Snips
Chapters
Transcript
Episode notes
Bristol Myers Q1 Performance Analysis
- Bristol Myers delivered a strong quarter beating revenue and earnings and raised their full-year guidance.
- The beat stemmed from old drugs like Revlimid and the growth portfolio, but new drug prospects warrant a "show me" stance.
Trial Impact on Drug Portfolio
- The ARISE schizophrenia trial is downplayed by Bristol Myers as monotherapy dominates 70-80% of the market.
- They do not see a risk from ARISE's results nor impact on their Alzheimer's psychosis strategy.
Cramer's Confidence in Bristol Myers
- Jim Cramer has not lost confidence in Bristol Myers, unlike other companies like GE Healthcare or Constellation Brands.
- He views Bristol Myers' management as good people and prefers to wait before making drastic moves.